Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | EVP & Chief Operating Officer | August 19, 2022 | August 22, 2022 |
| BIO-TECHNE CorpTECH · Entity 3479 | President - Diag & Spatial Bio | February 01, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date August 19, 2022 · Filed August 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMONSEC Table I · non-derivative | Direct | 29,467 |
Reported balance
After 2022-08-19 transaction · row 1
1 source rowRow 1 · 2022-08-19 · Purchase · Acquired 8,625 · Balance 29,467 F1: Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $57.99 to $58.32. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $57.99 to $58.32. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased at each separate price.
BIO-TECHNE Corp
Report date February 01, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,691 |
Ending reported balance
After 2026-02-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-01 · Exercise / conversion · Acquired 4,621 · Balance 9,356 Row 2 · 2026-02-01 · Tax withholding · Disposed 1,665 · Balance 7,691 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,620 |
Reported balance
After 2026-02-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-01 · Exercise / conversion · Disposed 4,621 · Balance 4,620 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3: 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,275 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 5,275 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6: 2,637 restricted stock units vest on 8/15/2026 and 2,638 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,622 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 9,622 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,888 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 2,888 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 15,825 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 15,825 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 19,243 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 19,243 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 7,951 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 7,951 F2: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.54 · Expires 2031-02-01 | Direct | 15,902 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 15,902 F4: Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 21,320 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 21,320 F7: Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 24,614 |
Reported balance
Holding disclosure · report date 2026-02-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 24,614 F10: Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F2: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F3: 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027.
F4: Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028.
F5: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F6: 2,637 restricted stock units vest on 8/15/2026 and 2,638 restricted stock units vest on 8/15/2027.
F7: Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
F8: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028.
F10: Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2026 Filed Feb 3, 2026 22:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 4,621 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000009 · form4.xml · derivative · entry 5 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,620 Underlying: Common Stock · 4,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027. F3 · derivative.expiration_date: 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,665 | $64.09 | $106,709.85 |
DisclosureSEC source: 0000914190-26-000009 · form4.xml · nonDerivative · entry 2 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,691 Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,621 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000009 · form4.xml · nonDerivative · entry 1 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 24,614 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 12 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,614 Underlying: Common Stock · 24,614 shares Expires 2035-08-15 F10 · derivative.exercise_date: Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 9,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 11 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,622 Underlying: Common Stock · 9,622 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028. F9 · derivative.expiration_date: 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 19,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 10 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,243 Underlying: Common Stock · 19,243 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F8 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · derivative · entry 8 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 2,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. F6 · derivative.expiration_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 880 | $53.60 | $47,168.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · nonDerivative · entry 2 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,735 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014698 · form4.xml · nonDerivative · entry 1 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001660 · form4.xml · derivative · entry 5 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,241 Underlying: Common Stock · 4,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. F3 · derivative.expiration_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,642 | $73.55 | $120,769.10 |
DisclosureSEC source: 0001062993-25-001660 · form4.xml · nonDerivative · entry 2 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,978 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001660 · form4.xml · nonDerivative · entry 1 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 21,320 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015380 · form4.xml · derivative · entry 7 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,320 Underlying: Common Stock · 21,320 shares Expires 2034-08-15 F7 · derivative.exercise_date: Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 7,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015380 · form4.xml · derivative · entry 6 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,912 Underlying: Common Stock · 7,912 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. F6 · derivative.expiration_date: 2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 15,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015380 · form4.xml · derivative · entry 5 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,818 Underlying: Common Stock · 15,818 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F5 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2024 Filed Feb 3, 2025 21:38 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 15,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001501 · form4a.xml · derivative · entry 1 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,825 Underlying: Common Stock · 15,825 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 15,902 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 4 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,902 Underlying: Common Stock · 15,902 shares Expires 2031-02-01 F4 · derivative.exercise_date: Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 7,951 | $0.00 Strike: $68.54 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 3 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,951 Underlying: Common Stock · 7,951 shares Expires 2031-02-01 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 13,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 2 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,861 Underlying: Common Stock · 13,861 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. F3 · derivative.expiration_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-002020 · form4.xml · derivative · entry 1 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,888 Underlying: Common Stock · 2,888 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 20:10 UTC | Azenta, Inc. AZTA · Entity 4724 | PurchaseCOMMON | 8,625 | $58.15 | $501,543.75 |
DisclosureSEC source: 0001209191-22-047012 · doc4.xml · nonDerivative · entry 1 McManus Matthew · CIK 0001908268 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,467 F1 · price: Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $57.99 to $58.32. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.